Last reviewed · How we verify

Basque Health Service — Portfolio Competitive Intelligence Brief

Basque Health Service pipeline: 2 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
levo-bupicaine levo-bupicaine marketed
Placebo evening Placebo evening marketed
ASA evening ASA evening phase 3 Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent Cyclooxygenase-1 (COX-1), Cyclooxygenase-2 (COX-2) Cardiovascular
Acetylsalicylic morning Acetylsalicylic morning phase 3 Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) Cardiovascular; Pain management; Inflammation
Placebos morning Placebos morning phase 3

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. Azienda Ospedaliera San Giovanni Battista · 1 shared drug class
  3. Biogen · 1 shared drug class
  4. Eli Lilly and Company · 1 shared drug class
  5. Harbin Medical University · 1 shared drug class
  6. Janssen Scientific Affairs, LLC · 1 shared drug class
  7. PLx Pharma · 1 shared drug class
  8. Royal College of Surgeons, Ireland · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Basque Health Service:

Cite this brief

Drug Landscape (2026). Basque Health Service — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/basque-health-service. Accessed 2026-05-16.

Related